Path: /institutions/diaxa-group
Type: Pharmaceutical and Diagnostics Company
Headquarters: Belo Horizonte, Minas Gerais, Brazil
Founded: 2012
Employees: ~450 (85 in R&D)
Overview
flowchart TD
institutions_diaxa_group["DIAXA Group"]
style institutions_diaxa_group fill:#4fc3f7,stroke:#333,color:#000
institutions_diaxa_g_0["Market Position and Business Model"]
institutions_diaxa_group -->|"includes"| institutions_diaxa_g_0
style institutions_diaxa_g_0 fill:#81c784,stroke:#333,color:#000
institutions_diaxa_g_1["Research Focus"]
institutions_diaxa_group -->|"includes"| institutions_diaxa_g_1
style institutions_diaxa_g_1 fill:#ef5350,stroke:#333,color:#000
institutions_diaxa_g_2["Alzheimers Disease Programs"]
institutions_diaxa_group -->|"includes"| institutions_diaxa_g_2
style institutions_diaxa_g_2 fill:#ffd54f,stroke:#333,color:#000
institutions_diaxa_g_3["Parkinsons Disease Programs"]
institutions_diaxa_group -->|"includes"| institutions_diaxa_g_3
style institutions_diaxa_g_3 fill:#ce93d8,stroke:#333,color:#000
institutions_diaxa_g_4["Diagnostic Innovation"]
institutions_diaxa_group -->|"includes"| institutions_diaxa_g_4
style institutions_diaxa_g_4 fill:#4fc3f7,stroke:#333,color:#000
institutions_diaxa_g_5["Pipeline Overview"]
institutions_diaxa_group -->|"includes"| institutions_diaxa_g_5
style institutions_diaxa_g_5 fill:#81c784,stroke:#333,color:#000
...Path: /institutions/diaxa-group
Type: Pharmaceutical and Diagnostics Company
Headquarters: Belo Horizonte, Minas Gerais, Brazil
Founded: 2012
Employees: ~450 (85 in R&D)
Overview
Mermaid diagram (expand to render)
DIAXA Group (Diagnósticos e Aplicações Axiais) is a Brazilian pharmaceutical and diagnostics company headquartered in Belo Horizonte, specializing in central nervous system (CNS) disorders. Founded in 2012, DIAXA has developed a strong portfolio of CNS therapeutics and diagnostic tools for [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). The company operates across three divisions: pharmaceutical products, diagnostic services, and research & development["@diaxa2024"].
The company's headquarters is located in the Savassi district of Belo Horizonte, a prominent healthcare and biotechnology hub in Brazil. DIAXA has invested significantly in building state-of-the-art laboratory facilities equipped for molecular biology, immunology, and neuroimaging research. This infrastructure supports both internal R&D programs and collaborative projects with academic and industry partners throughout Brazil and internationally.
Market Position and Business Model
DIAXA holds a significant position in the Brazilian CNS market, with annual revenues of approximately R$180 million (USD 36 million). The company's diagnostic services are available in over 500 healthcare facilities across Brazil, and their pharmaceutical products are distributed through major pharmacy chains and hospital pharmacies nationwide. This dual revenue stream provides financial stability while the company advances its pipeline of novel therapeutics[@diaxa2024].
The company's business model leverages Brazil's unique position in global healthcare markets. By focusing on diseases with high prevalence in Latin America, DIAXA addresses unmet medical needs while benefiting from regulatory incentives for domestic pharmaceutical development. The company's diagnostic division serves as a cash flow engine, funding the more capital-intensive drug development programmes while providing valuable real-world data on patient populations.
Research Focus
Alzheimer's Disease Programs
DIAXA's lead program is DXA-401, a [tau aggregation inhibitor](/mechanisms/tau-aggregation) in preclinical development for [Alzheimer's disease](/diseases/alzheimers-disease). Tau protein pathology, including [neurofibrillary tangles](/mechanisms/tau-pathology), is a hallmark of Alzheimer's disease and correlates strongly with cognitive decline. DXA-401 targets the abnormal aggregation of tau proteins into toxic oligomers and fibrils, potentially preventing the spread of tau pathology throughout the brain. Preclinical studies in transgenic mouse models have shown promising results, with reduced tau pathology and improved cognitive performance[@lima2023].
Parkinson's Disease Programs
For [Parkinson's disease](/diseases/parkinsons-disease), DIAXA is developing DXA-501, a [neuroinflammatory modulator](/mechanisms/neuroinflammation) targeting the microglial activation pathways that contribute to dopaminergic neuron loss. The company's research has identified specific cytokine pathways that are hyperactive in Parkinson's disease patients, and DXA-501 is designed to normalize these responses without compromising the essential immune surveillance functions of microglia.
Diagnostic Innovation
DIAXA's diagnostic division has developed the Dx-Alzheimers Blood Test, an FDA-cleared diagnostic panel using peripheral blood markers to support early [Alzheimer's](/diseases/alzheimers-disease) diagnosis. This test measures a panel of protein [biomarkers](/biomarkers/) associated with [amyloid](/mechanisms/amyloid-beta-aggregation) and [tau pathology](/mechanisms/tau-pathology), providing a non-invasive screening tool that can identify patients likely to benefit from further diagnostic evaluation. The test has shown sensitivity of 85% and specificity of 90% in clinical validation studies[@fda2023][@oliveira2024].
Pipeline Overview
| Programme | Indication | Stage | Mechanism |
|-----------|-----------|-------|----------|
| Dx-Alzheimers Blood Test | [Alzheimer's disease](/diseases/alzheimers-disease) | FDA Cleared | Blood biomarker panel |
| DXA-401 | [Alzheimer's disease](/diseases/alzheimers-disease) | Preclinical | [Tau aggregation](/mechanisms/tau-aggregation) inhibition |
| DXA-501 | [Parkinson's disease](/diseases/parkinsons-disease) | Discovery | [Neuroinflammatory](/mechanisms/neuroinflammation) modulation |
Strategic Partnerships
DIAXA has established partnerships with leading Brazilian research institutions and healthcare organizations. The Federal University of Minas Gerais (UFMG) hosts a joint [biomarker](/biomarkers/) research program, leveraging the university's expertise in proteomics and neurodegeneration research. The Albert Einstein Israeli Hospital provides clinical validation capabilities for new diagnostic panels, while commercial partnerships with Aché Laboratórios ensure effective market reach for approved pharmaceutical products[@diaxa2024].
These partnerships reflect DIAXA's strategy of building an integrated innovation ecosystem rather than operating in isolation. By connecting academic research, clinical validation, and commercial execution, the company aims to accelerate the translation of scientific discoveries into patient benefits.
Leadership
DIAXA is led by Dr. Fernanda Oliveira (CEO), a pharmacologist with 25 years of experience in the pharmaceutical industry. Dr. Oliveira previously held senior positions at major pharmaceutical companies and brings expertise in drug development, regulatory affairs, and commercial strategy. The Chief Scientific Officer, Dr. Rodrigo Lima, is an internationally recognized expert in [neuroinflammation](/mechanisms/neuroinflammation) with over 100 publications in peer-reviewed journals[@lima2023].
Financial Overview
DIAXA has raised R$85 million in total funding, including R$45 million in Series B financing completed in 2023. The company's investors include Brazilian venture capital funds and strategic pharmaceutical partners. Revenue growth has been steady at 15-20% annually, driven primarily by the diagnostic division. The company plans to seek listing on B3 (Brazilian Stock Exchange) within the next three years[@diaxa2024].
Cross-Links
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Tau Aggregation](/mechanisms/tau-aggregation)
- [Neurofibrillary Tangles](/mechanisms/tau-pathology)
- [Blood Biomarkers](/biomarkers/)